Download BIBLIOGRAFIA

1
Referencias
1) Friedewald, V. E., Cather, J. C., Gelfand, J. M. et al. AJC Editor’s
Consensus: Psoriasis and coronary artery disease. Am J Cardiol 2008;
102:1631-1643
2) Shelling, M. L., Federman, D. G., Prodanovich, S. et al. Psoriasis and
vascular disease: An unsolved mystery. Am J Med 2008; 121:360-365.
3) Kimball, A. B., Wu, Y. Cardiovascular disease and classic ardiovascular risk
factors in patients with psoriasis. IntJ Dermatol 2009; 48:1147-1156.
4) Prodanovich, S., Kisrner, R. S., Kravetz, J. D. et al. Association of psoriasis
with coronary artery, cerebrovascular and peripheral vascular diseases and
mortality. Arch Dermatol2009; 145(6):700-703.
5) Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:
115-126.
6) Libby P., Ridker PM. Inflammation and atherosclerosis. Circulation 2002;
105: 1135-1143.
7) Libby P. Molecular basis of the acute coronary syndromes. Circulation 1995;
91: 2844-2850.
8) Fernández Ortiz A., Fuster V. Characterization of the relative thrombogenicity
of atherosclerotic plaque components, implications for consequences of plaque
rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
2
9) Hannson G, Yokota T. Cytokines and the cardiovascular system. In: Remik
DG, Friedland JS (eds). Cytokines, Marcel Decker Inc 1997; 507-518.
10) Ross R. The pathogenesis of atherosclerosis: a perspective from the 1990s.
Nature 1993; 362: 801-809.
11) Valhoutte PM. Endothelium dysfunction and atherosclerosis. Eur Heart J
1997; 18: E19-E29.
12) Wick G, Millonig G, Hannes P. Atherosclerosis as an autoimmune disease:
an update. Trends in Immunology 2001; 22: 665-669.
13) Hansson GK., Libby P. Innate and adaptive immunity in the pathogenesis of
atherosclerosis. Circ Res 2002; 91: 281-291.
14) Hansson GK. Immune mechanism in atherosclerosis. Arterioscler Thromb
Vasc Biol 2001; 21: 1876-1890.
15) Yamashita H., Shimada K., Seki E., et al. Concentrations of interleukins,
interferon, and C-reactive protein in stable and unstable angina pectoris. Am J
Card 2003; 91: 133-136.
16) Davies MJ., Richardson PD. Risk of thrombosis in human atherosclerotic
plaques: role of extracellular lipid, macrophage, and smooth muscle cell
content. Br Heart J 1993; 69: 377-381.
17) Sharma R., Da-Zhu Li. Role of dendritic cells in atherosclerosis. Asian
Cardiovasc Thorac Ann 2006; 14: 166-169.
3
18) Millonig G., Niederreger H., Wick G. Network of vascular associated
dendritic cells in intima of healthy young individuals. Arterioscler Thromb Vasc
Biol 2001; 21: 503-508.
19) Ludwig RJ., Herzog C., Rostock A. et al. Psoriasis: a possible risk factor for
development of coronary artery calcification. Br J Dermatol 2007; 156:271-276.
20) Mallbris L., Akre O., Granath F. et al., “Increased risk for cardiovascular
mortality in psoriasis inpatients but no in outpatients”. Eur J Epidemiol 2004;
19:225-23.
21) Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic
mechanisms and potential for an integrated treatment approach. B J Dermatol
2008;159:10-17.
22) Biedermann T., Röcken M., Carballido JM. Th1 and Th2 lymphocyte
development and regulation of Th cell-mediated immune responses of the skin.
J Invest Dermatol 2004;9:5-14.
23) Gudjonsson JE., Johnston A,, Sigmundsdotir H., et al. Immunopathogenic
mechanisms in psoriasis. Clin Experience Immunol 2004;135:1-8.
24) Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb
Vasc Biol 2001;21:1876-90.
25) Gelfand JM., Troxel AB., Lewis JD. et al. The risk of mortality in patients
with psoriasis: results from a population-based study. Arch Dermatol 2007;
143:1493-1499.CA
4
26) Vena, A. Vestita M., Cassano N. Psoriasis and Cardiovascular disease.
Dermatol Ther 2010;23:144-151.
27) Gelfand JM., Neimann AL., Shin DB. et al. Risk of myocardial infarction in
patients with psoriasis. JAMA2006; 6(14):1735-1741.
28) El-Mongy S, Fathy H, Abdelaziz A, et al. Subclinical atherosclerosis in
patients with chronic psoriasis: a potential association. JEADV 2010;24:661666.
29) Gisondi P., Fantin F, Del Giglio M et al. Chronic plaque psoriasis is
associated with increased arterial stiffness. Dermatology 2009; 218:110-113.
30) Gonzalez-Juanatey C., Llorca J., Miranda-Filloy JA. et al. Endothelial
dysfunction in psoriatic arthritis patients without clinically evident cardiovascular
disease or classic atherosclerosis risk factors. Arthritis Rheum2007; 57(2):287293.
31) Busso C. Psoriasis y enfermedad aterosclerótica: su asociación con el
incremento del riesgo. Nuevas perspectivas, en Esper R, Kotliar C, Barontini M,
Forcada
P.
Tratado
de
Mecánica
Vascular
e
Hipertensión
Arterial.
Ed.Inter.Médica, Buenos Aires, 2010: 717-722.
32) Pearson TA., Blair SN., Daniels SR. et al. AHA guidelines for primary
prevention of cardiovascular disease and stroke: 2002 update. Consensus
panel guide to comprehensive risk reduction for adult patients without coronary
or other atherosclerotic vascular diseases. Circulation 2002;106:388-391.
5
33) Maradit Kremers H., McEvoy MT., Dann FJ. et al. Heart disease in
psoriasis. J Am Acad Dermatol 2007; 57:347-354.6 SECCION CLINICA